What's Going On With Kazia Therapeutics Shares Thursday?
What's Going On With Kazia Therapeutics Shares Thursday?
Kazia Therapeutics (NASDAQ:KZIA) stock is trading higher on Thursday on possible continued momentum from the company's Wednesday press release.
kazia therapeutics (納斯達克:KZIA)股票週四交易較高，可能受週三公司新聞發佈會的持續推動。
The Details: The company announced results from its Phase II/III trial in regards to the treatment of glioblastoma, a type of brain cancer.
詳情：該公司發佈了其II/III期試驗有關治療膠質母細胞瘤（一種腦癌）的結果。
The trial, containing 313 participants, compared the effectiveness of paxalisib versus the current standard of care. The results showed a 3.8 month increase in overall survival, or about a 33% improvement. The median overall survival was 14.77 months for paxalisib-treated patients compared to 13.84 months for patients treated with standard care.
試驗共有313名參與者，比較了帕可司坦與目前的標準治療的有效性。結果顯示總生存期增長了3.8個月，即改善了約33%。帕可司坦治療的患者的中位總生存期爲14.77個月，而標準治療的患者爲13.84個月。
In a preplanned additional analysis, the median overall survival was 15.54 months for those treated with paxalisib compared to 11.89 months for those receiving standard care. A sensitivity analysis also showed similar results: 15.54 months for paxalisib-treated patients and 11.70 months for those on standard care.
在一次預先安排的額外分析中，接受帕可司坦治療的患者的中位總生存期爲15.54個月，而接受標準治療的患者爲11.89個月。敏感性分析也顯示了類似的結果：接受帕可司坦治療的患者中位總生存期爲15.54個月，接受標準治療的患者爲11.70個月。
These findings match the results from an earlier phase II study by the company.
這些發現與該公司早期II期研究的結果相符。
"Having comparable Overall Survival data across two independent studies is a compelling outcome in this difficult to treat glioblastoma population. We look forward to discussing possible approaches for an accelerated approval pathway for paxalisib with the FDA," said Kazia CEO John Friend.
“在兩個獨立研究中擁有可比的總生存數據是在難治性膠質母細胞瘤人群中取得的一個引人注目的結果。我們期待與FDA討論帕可司坦的加速批准途徑可能的途徑，” Kazia首席執行官約翰·弗倫德表示。
KZIA Price Action: At the time of publication, Kazia Therapeutics shares are trading 58.5% higher at $1.06 per data from Benzinga Pro.
Kazia Therapeutics股票價格走勢：根據Benzinga Pro的數據，截止本文發表時，Kazia Therapeutics股價上漲了58.5%，爲每股1.06美元。
- UniQure Soars on New Huntington's Disease Study Data
- UniQure對亨廷頓病新研究數據的飆升
Image: Akava Photo from Pixabay
圖片來自Pixabay的Akava照片。